In conclusion, we found that irAEs of PD-1/PD-L1 inhibitors for lung cancer were mainly low grade and that the occurrence of irAE was positively correlated with ORR, DCR, and PFS, suggesting that patients with irAEs are more likely to benefit from immunotherapy. This evidence concerns the gene PDCD1 and lung cancer.